Free Trial

Humana (HUM) Financials

Humana logo
$227.88 +1.27 (+0.56%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$230.44 +2.56 (+1.12%)
As of 08:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Humana

Annual Income Statements for Humana

This table shows Humana's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
1,207 2,489 2,806 2,933 3,367 2,707 1,683 2,448 614 1,276
Consolidated Net Income / (Loss)
1,214 2,484 2,802 2,934 3,367 2,707 1,683 2,448 614 1,276
Net Income / (Loss) Continuing Operations
1,214 2,484 2,802 2,934 3,367 2,707 1,683 2,448 614 1,276
Total Pre-Tax Income
1,721 3,383 3,568 3,354 4,600 3,456 2,063 4,020 1,552 2,431
Total Operating Income
2,562 4,013 3,800 3,148 4,986 3,192 3,100 4,262 1,741 2,347
Total Gross Profit
17,097 17,980 17,180 13,865 15,527 11,031 11,030 10,271 9,372 10,020
Total Revenue
117,761 106,374 92,870 83,064 77,155 64,888 56,912 53,767 54,379 54,289
Operating Revenue
116,535 105,305 92,488 82,877 76,001 64,387 56,912 53,767 54,379 54,289
Other Revenue
1,226 1,069 382 187 1,154 - - - - -
Total Cost of Revenue
100,664 88,394 75,690 69,199 61,628 53,857 45,882 43,496 45,007 44,269
Operating Cost of Revenue
100,664 88,394 75,690 69,199 61,628 53,857 45,882 43,496 45,007 44,269
Total Operating Expenses
14,535 13,967 13,380 10,717 10,541 7,839 7,930 6,009 7,631 7,673
Selling, General & Admin Expense
13,696 13,188 12,671 10,121 10,052 7,381 7,525 6,567 7,173 7,295
Depreciation Expense
839 779 709 596 489 458 405 378 354 355
Total Other Income / (Expense), net
-841 -630 -232 206 -386 264 -1,037 -242 -189 84
Interest Expense
660 493 401 326 283 242 218 242 189 186
Other Income / (Expense), net
-181 -137 169 532 -103 506 -819 0.00 0.00 270
Income Tax Expense
413 836 762 485 1,307 763 391 1,572 938 1,155
Other Gains / (Losses), net
-94 -63 -4.00 65 74 14 11 0.00 - -
Net Income / (Loss) Attributable to Noncontrolling Interest
7.00 -5.00 -4.00 1.00 0.00 0.00 - - - -
Basic Earnings per Share
$10.01 $20.09 $22.20 $22.79 $25.47 $20.20 $12.24 $16.94 $4.11 $8.54
Weighted Average Basic Shares Outstanding
120.64M 120.65M 124.97M 126.63M 128.86M 132.11M 137.49M 144.49M 149.38M 149.46M
Diluted Earnings per Share
$9.98 $20.00 $22.08 $22.67 $25.31 $20.10 $12.16 $16.81 $4.07 $8.44
Weighted Average Diluted Shares Outstanding
120.64M 120.65M 124.97M 126.63M 128.86M 132.11M 137.49M 144.49M 149.38M 149.46M
Weighted Average Basic & Diluted Shares Outstanding
120.64M 120.65M 124.97M 126.63M 128.86M 132.11M 137.49M 144.49M 149.38M 149.46M
Cash Dividends to Common per Share
$3.54 $3.44 $3.06 $2.73 $2.43 $2.15 $1.90 $1.49 $1.16 $1.14

Quarterly Income Statements for Humana

This table shows Humana's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
1,244 -693 480 679 741 -541 832 959 1,239 -15 1,195
Consolidated Net Income / (Loss)
1,242 -683 480 678 739 -540 830 956 1,238 -18 1,193
Net Income / (Loss) Continuing Operations
1,242 -683 480 678 739 -540 830 956 1,238 -18 1,193
Total Pre-Tax Income
1,691 -862 651 918 1,014 -591 1,098 1,262 1,614 -71 1,297
Total Operating Income
2,014 -543 728 1,141 1,236 -348 1,206 1,436 1,719 124 1,172
Total Gross Profit
5,577 3,832 4,277 4,501 4,487 3,680 4,678 4,738 4,884 3,857 4,415
Total Revenue
32,112 29,213 29,397 29,540 29,611 26,462 26,423 26,747 26,742 22,439 22,799
Operating Revenue
31,848 28,916 29,054 29,242 29,323 26,168 26,115 26,473 26,549 22,279 22,627
Other Revenue
264 297 343 298 288 294 308 274 193 - 172
Total Cost of Revenue
26,535 25,381 25,120 25,039 25,124 22,782 21,745 22,009 21,858 18,582 18,384
Operating Cost of Revenue
26,535 25,381 25,120 25,039 25,124 22,782 21,745 22,009 21,858 18,582 18,384
Total Operating Expenses
3,563 4,375 3,549 3,360 3,251 4,028 3,472 3,302 3,165 3,733 3,243
Selling, General & Admin Expense
3,380 4,167 3,339 3,148 3,042 3,827 3,271 3,111 2,979 3,551 3,061
Depreciation Expense
183 208 210 212 209 201 201 191 186 182 182
Total Other Income / (Expense), net
-323 -319 -77 -223 -222 -243 -108 -174 -105 -195 125
Interest Expense
160 164 169 168 159 146 114 120 113 108 102
Other Income / (Expense), net
-163 -155 92 -55 -63 -97 6.00 -54 8.00 -87 227
Income Tax Expense
406 -216 155 223 251 -75 256 296 359 -58 107
Other Gains / (Losses), net
-43 -37 -16 -17 -24 -24 -12 -10 -17 -5.00 3.00
Net Income / (Loss) Attributable to Noncontrolling Interest
-2.00 10 0.00 -1.00 -2.00 1.00 -2.00 -3.00 -1.00 -3.00 -2.00
Basic Earnings per Share
$10.31 ($5.74) $3.99 $5.63 $6.13 ($4.26) $6.74 $7.70 $9.91 ($0.07) $9.45
Weighted Average Basic Shares Outstanding
120.69M 120.64M 120.41M 120.40M 120.50M 120.65M 123.11M 123.91M 124.94M 124.97M 126.60M
Diluted Earnings per Share
$10.30 ($5.73) $3.98 $5.62 $6.11 ($4.24) $6.71 $7.66 $9.87 ($0.08) $9.39
Weighted Average Diluted Shares Outstanding
120.69M 120.64M 120.41M 120.40M 120.50M 120.65M 123.11M 123.91M 124.94M 124.97M 126.60M
Weighted Average Basic & Diluted Shares Outstanding
120.69M 120.64M 120.41M 120.40M 120.50M 120.65M 123.11M 123.91M 124.94M 124.97M 126.60M

Annual Cash Flow Statements for Humana

This table details how cash moves in and out of Humana's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
-2,473 -367 1,667 -1,279 619 1,711 -1,699 165 1,306 636
Net Cash From Operating Activities
2,966 3,981 4,587 2,262 5,639 5,284 2,173 4,051 1,936 868
Net Cash From Continuing Operating Activities
2,966 3,981 4,587 2,262 5,639 5,284 2,173 4,051 1,936 868
Net Income / (Loss) Continuing Operations
1,214 2,484 2,802 2,934 3,367 2,707 1,683 2,448 614 1,276
Consolidated Net Income / (Loss)
1,214 2,484 2,802 2,934 3,367 2,707 1,683 2,448 614 1,276
Depreciation Expense
908 850 749 640 528 505 444 410 388 354
Amortization Expense
60 67 96 73 88 70 90 75 77 93
Non-Cash Adjustments To Reconcile Net Income
714 553 436 -884 -731 51 822 241 58 -246
Changes in Operating Assets and Liabilities, net
70 27 504 -501 2,387 1,951 -866 877 799 -609
Net Cash From Investing Activities
-2,952 -3,492 -1,006 -6,556 -3,065 -1,278 -3,087 -2,941 -1,362 320
Net Cash From Continuing Investing Activities
-2,952 -3,492 -1,006 -6,556 -3,065 -1,278 -3,087 -2,941 -1,362 320
Purchase of Property, Plant & Equipment
-575 -1,004 -1,137 -1,342 -964 -736 -612 -524 -527 -523
Acquisitions
-89 -233 -337 -4,187 -709 0.00 -2,254 -31 -7.00 -38
Purchase of Investments
-8,603 -7,552 -6,049 -7,197 -9,125 -6,361 -4,687 -6,265 -6,566 -6,739
Sale of Property, Plant & Equipment
7.00 210 17 26 - - - - - 1.00
Divestitures
0.00 0.00 2,701 0.00 0.00 - - 0.00 0.00 1,061
Sale and/or Maturity of Investments
6,358 5,087 3,799 6,144 7,733 5,819 4,466 3,879 5,738 6,558
Other Investing Activities, net
-50 0.00 0.00 - - - - - - -
Net Cash From Financing Activities
-2,487 -856 -1,914 3,015 -1,955 -2,295 -785 -945 732 -552
Net Cash From Continuing Financing Activities
-2,487 -856 -1,914 3,015 -1,955 -2,295 -785 -945 732 -552
Repayment of Debt
-2,129 -2,379 -3,373 -1,736 -1,056 -1,410 -350 -953 -2.00 298
Repurchase of Common Equity
-817 -1,573 -2,096 -79 -1,820 -1,070 -1,090 -3,365 -104 -385
Payment of Dividends
-431 -431 -392 -354 -323 -291 -265 -220 -177 -172
Issuance of Debt
2,232 2,644 1,982 5,484 2,088 987 1,485 1,779 0.00 0.00
Other Financing Activities, net
-1,342 883 1,965 -300 -844 -511 -565 1,814 1,015 -293
Cash Interest Paid
584 394 354 285 258 212 195 216 185 187
Cash Income Taxes Paid
570 997 758 227 1,132 518 631 1,498 916 1,179

Quarterly Cash Flow Statements for Humana

This table details how cash moves in and out of Humana's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
2,029 -2,895 -385 -409 1,216 -10,454 -1,066 2,479 8,674 -8,497 8,338
Net Cash From Operating Activities
331 -528 1,858 1,213 423 -7,134 1,252 3,176 6,687 -5,127 8,453
Net Cash From Continuing Operating Activities
331 -528 1,858 1,213 423 -7,134 1,252 3,176 6,687 -5,127 8,453
Net Income / (Loss) Continuing Operations
1,242 -683 480 678 739 -540 830 956 1,238 -18 1,193
Consolidated Net Income / (Loss)
1,242 -683 480 678 739 -540 830 956 1,238 -18 1,193
Depreciation Expense
200 226 228 228 226 222 218 210 200 194 186
Amortization Expense
15 14 15 15 16 16 17 16 18 23 28
Non-Cash Adjustments To Reconcile Net Income
99 385 101 127 101 292 -6,992 7,138 115 224 -170
Changes in Operating Assets and Liabilities, net
-1,225 -470 1,034 165 -659 -7,124 7,179 -5,144 5,116 -5,550 7,216
Net Cash From Investing Activities
314 -63 -1,473 -1,002 -414 -882 -585 -733 -1,292 -1,012 1,676
Net Cash From Continuing Investing Activities
314 -63 -1,473 -1,002 -414 -882 -585 -733 -1,292 -1,012 1,676
Purchase of Property, Plant & Equipment
-95 -154 -130 -114 -177 -283 -234 -264 -223 -275 -288
Acquisitions
0.00 -52 -20 -3.00 -14 -10 -34 -116 -73 -44 -126
Purchase of Investments
-1,002 -2,200 -3,441 -1,703 -1,259 -4,186 -629 -1,424 -1,313 -1,309 -1,501
Sale and/or Maturity of Investments
1,411 2,386 2,118 818 1,036 3,387 312 1,071 317 606 883
Net Cash From Financing Activities
1,384 -2,304 -770 -620 1,207 -2,438 -1,733 36 3,279 -2,358 -1,791
Net Cash From Continuing Financing Activities
1,384 -2,304 -770 -620 1,207 -2,438 -1,733 36 3,279 -2,358 -1,791
Repayment of Debt
-19 -1,440 261 -272 -678 -1,639 -5.00 112 -847 -698 -2,244
Repurchase of Common Equity
-9.00 -49 -2.00 -49 -717 -571 -379 -529 -94 -1,064 -4.00
Payment of Dividends
-108 -108 -107 -107 -109 -111 -109 -111 -100 -101 -100
Issuance of Debt
1,481 - - - 2,232 1,429 - - 1,215 1,238 -
Other Financing Activities, net
39 -707 -922 -192 479 -1,546 -1,240 564 3,105 -1,733 557
Cash Interest Paid
143 168 166 92 158 77 142 78 97 98 85
Cash Income Taxes Paid
-12 - 208 361 1.00 40 276 675 6.00 7.00 378

Annual Balance Sheets for Humana

This table presents Humana's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
46,479 47,065 43,055 44,358 34,969 29,074 25,413 27,178 25,396 24,678
Total Current Assets
29,815 29,986 26,183 24,893 23,641 19,888 16,948 17,402 16,190 15,711
Cash & Equivalents
2,221 4,694 5,061 3,394 4,673 4,054 2,343 4,042 3,877 2,571
Short-Term Investments
18,214 16,626 13,881 13,192 12,554 10,972 10,026 9,557 7,595 7,267
Accounts Receivable
2,704 2,035 1,674 1,814 1,138 1,056 1,015 854 1,280 1,161
Other Current Assets
6,676 6,631 5,567 6,493 5,276 3,806 3,564 2,949 3,438 4,712
Plant, Property, & Equipment, net
2,532 3,030 3,221 3,073 2,371 1,955 1,735 1,584 1,505 1,384
Total Noncurrent Assets
14,132 14,049 13,651 16,392 8,957 7,231 6,730 8,192 7,701 7,583
Long-Term Investments
1,118 1,122 1,129 921 2,382 1,469 1,458 2,745 2,203 1,843
Goodwill
9,631 9,550 9,142 11,092 4,447 3,928 3,897 3,281 3,272 3,265
Other Noncurrent Operating Assets
3,383 3,377 3,380 4,379 2,128 1,834 1,375 2,166 2,226 2,475
Total Liabilities & Shareholders' Equity
46,479 47,065 43,055 44,358 34,969 29,074 25,413 27,178 25,396 24,678
Total Liabilities
30,034 30,747 27,685 28,255 21,241 17,037 15,252 17,336 14,711 14,332
Total Current Liabilities
16,939 18,872 17,178 15,331 13,394 10,929 10,077 9,406 7,822 8,152
Short-Term Debt
577 1,443 2,092 1,953 600 699 1,694 291 512 600
Accounts Payable
5,259 6,569 5,238 4,509 4,013 3,754 3,067 4,069 2,467 2,212
Current Deferred Revenue
260 266 286 254 318 247 283 378 280 364
Other Current Liabilities
10,843 10,594 9,562 8,615 8,463 6,229 5,033 4,668 4,563 4,976
Total Noncurrent Liabilities
13,095 11,875 10,507 12,924 7,847 6,108 5,175 7,930 6,889 6,180
Long-Term Debt
11,144 10,213 9,034 10,541 6,060 4,967 4,375 4,770 3,792 3,794
Other Noncurrent Operating Liabilities
1,951 1,662 1,473 2,383 1,787 1,141 800 3,160 3,097 2,386
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
16,445 16,318 15,370 16,103 13,728 12,037 10,161 9,842 10,685 10,346
Total Preferred & Common Equity
16,375 16,262 15,311 16,080 13,728 12,037 10,161 9,842 10,685 10,346
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
16,375 16,262 15,311 16,080 13,728 12,037 10,161 9,842 10,685 10,346
Common Stock
3,496 3,379 3,279 3,115 2,738 2,853 2,568 2,478 2,595 2,563
Retained Earnings
28,317 27,540 25,492 23,086 20,517 17,483 15,072 13,670 11,454 11,017
Treasury Stock
-14,371 -13,658 -12,156 -10,163 -9,918 -8,455 -7,320 -6,325 -3,298 -3,292
Accumulated Other Comprehensive Income / (Loss)
-1,067 -999 -1,304 42 391 156 -159 19 -66 58
Noncontrolling Interest
70 56 59 23 0.00 - - - - -

Quarterly Balance Sheets for Humana

This table presents Humana's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
50,930 46,479 50,007 50,093 50,091 47,065 55,905 56,455 54,776 43,055 50,765
Total Current Assets
34,422 29,815 32,926 32,858 32,796 29,986 38,253 38,759 37,532 26,183 33,711
Cash & Equivalents
4,250 2,221 5,116 5,501 5,910 4,694 15,148 16,214 13,735 5,061 13,558
Short-Term Investments
17,888 18,214 19,033 17,424 16,697 16,626 15,145 15,251 14,932 13,881 13,124
Accounts Receivable
4,459 2,704 2,144 4,090 3,925 2,035 1,824 1,429 3,107 1,674 1,609
Other Current Assets
7,825 6,676 6,633 5,843 6,264 6,631 6,136 5,865 5,758 5,567 5,420
Plant, Property, & Equipment, net
2,427 2,532 2,693 2,821 2,979 3,030 3,342 3,309 3,234 3,221 3,218
Total Noncurrent Assets
14,081 14,132 14,388 14,414 14,316 14,049 14,310 14,387 14,010 13,651 13,836
Long-Term Investments
1,069 1,118 1,129 1,124 1,110 1,122 1,132 1,122 1,110 1,129 1,113
Goodwill
9,631 9,631 9,590 9,567 9,563 9,550 9,540 9,539 9,320 9,142 9,096
Other Noncurrent Operating Assets
3,381 3,383 3,669 3,723 3,643 3,377 3,638 3,726 3,580 3,380 3,627
Total Liabilities & Shareholders' Equity
50,930 46,479 50,007 50,093 50,091 47,065 55,905 56,455 54,776 43,055 50,765
Total Liabilities
33,111 30,034 32,383 33,365 33,905 30,747 38,901 39,564 38,142 27,685 34,448
Total Current Liabilities
18,043 16,939 18,727 19,790 19,689 18,872 27,823 28,279 26,942 17,178 25,051
Short-Term Debt
577 577 1,136 1,149 822 1,443 2,245 2,022 1,867 2,092 2,799
Accounts Payable
5,380 5,259 5,915 6,527 6,504 6,569 7,600 8,118 7,431 5,238 6,766
Current Deferred Revenue
265 260 195 313 301 266 7,536 7,378 7,220 286 6,012
Other Current Liabilities
11,821 10,843 11,481 11,801 12,062 10,594 10,442 10,761 10,424 9,562 9,474
Total Noncurrent Liabilities
15,068 13,095 13,656 13,575 14,216 11,875 11,078 11,285 11,200 10,507 9,397
Long-Term Debt
12,729 11,144 11,886 11,746 12,390 10,213 9,483 9,722 9,743 9,034 7,798
Other Noncurrent Operating Liabilities
2,339 1,951 1,770 1,829 1,826 1,662 1,595 1,563 1,457 1,473 1,599
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 - - - 0.00 -
Total Equity & Noncontrolling Interests
17,819 16,445 17,624 16,728 16,186 16,318 17,004 16,891 16,634 15,370 16,317
Total Preferred & Common Equity
17,751 16,375 17,565 16,671 16,130 16,262 16,949 16,834 16,577 15,311 16,254
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
17,751 16,375 17,565 16,671 16,130 16,262 16,949 16,834 16,577 15,311 16,254
Common Stock
3,530 3,496 3,504 3,453 3,402 3,379 3,395 3,346 3,295 3,279 3,267
Retained Earnings
29,453 28,317 29,118 28,745 28,173 27,540 28,191 27,468 26,619 25,492 25,606
Treasury Stock
-14,364 -14,371 -14,404 -14,405 -14,359 -13,658 -13,134 -12,754 -12,224 -12,156 -11,152
Accumulated Other Comprehensive Income / (Loss)
-868 -1,067 -653 -1,122 -1,086 -999 -1,503 -1,226 -1,113 -1,304 -1,467
Noncontrolling Interest
68 70 59 57 56 56 55 57 57 59 63

Annual Metrics And Ratios for Humana

This table displays calculated financial ratios and metrics derived from Humana's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
10.70% 14.54% 11.81% 7.66% 18.90% 14.01% 5.85% -1.13% 0.17% 11.94%
EBITDA Growth
-30.13% -0.44% 9.58% -20.11% 28.69% 51.79% -40.70% 115.19% -28.00% 9.00%
EBIT Growth
-38.57% -2.34% 7.85% -24.64% 32.04% 62.12% -46.48% 144.80% -33.47% 10.80%
NOPAT Growth
-35.55% 1.10% 10.98% -24.56% 43.50% -1.00% -3.19% 276.81% -44.09% -1.33%
Net Income Growth
-51.13% -11.35% -4.50% -12.86% 24.38% 60.84% -31.25% 298.70% -51.88% 11.25%
EPS Growth
-50.10% -9.42% -2.60% -10.43% 25.92% 65.30% -27.66% 313.02% -51.78% 14.67%
Operating Cash Flow Growth
-25.50% -13.21% 102.79% -59.89% 6.72% 143.17% -46.36% 109.25% 123.04% -46.35%
Free Cash Flow Firm Growth
-77.87% -48.86% 200.46% -290.54% 8.58% 376.54% -124.89% 119.84% 1,109.48% -123.10%
Invested Capital Growth
19.54% -13.90% -42.06% 1,323.62% -35.51% -49.73% 266.76% -209.67% -57.04% 92.88%
Revenue Q/Q Growth
2.39% 3.93% 1.51% 2.46% 3.72% 3.39% 1.75% 0.58% -0.88% 1.94%
EBITDA Q/Q Growth
-6.97% -8.77% 0.61% 11.44% -15.61% 3.94% -23.44% 27.20% -24.66% 6.09%
EBIT Q/Q Growth
-9.61% -11.06% 0.15% 12.78% -17.52% 4.40% -27.56% 30.82% -29.46% 7.74%
NOPAT Q/Q Growth
-2.16% -13.80% 1.85% 11.78% -13.33% -3.17% 12.38% 30.16% -42.88% -5.02%
Net Income Q/Q Growth
-10.54% -17.37% -0.18% 9.76% -18.93% 6.16% 11.31% 31.40% -44.98% -3.33%
EPS Q/Q Growth
-12.99% -17.22% 0.14% 9.36% -18.93% 6.74% 10.65% 31.95% -45.00% -3.32%
Operating Cash Flow Q/Q Growth
181.48% -33.52% -52.31% -14.35% -3.90% 19.04% 636.54% -3.29% -61.63% 19.89%
Free Cash Flow Firm Q/Q Growth
114.27% -26.38% -41.56% -20.68% -1.86% 35.04% 60.01% -11.91% -56.54% 18.54%
Invested Capital Q/Q Growth
23.19% 305.42% 829.28% 19.48% 39.11% 134.11% 256.53% 70.54% 262.02% -14.62%
Profitability Metrics
- - - - - - - - - -
Gross Margin
14.52% 16.90% 18.50% 16.69% 20.12% 17.00% 19.38% 19.10% 17.23% 18.46%
EBITDA Margin
2.84% 4.51% 5.18% 5.29% 7.13% 6.59% 4.95% 8.83% 4.06% 5.64%
Operating Margin
2.18% 3.77% 4.09% 3.79% 6.46% 4.92% 5.45% 7.93% 3.20% 4.32%
EBIT Margin
2.02% 3.64% 4.27% 4.43% 6.33% 5.70% 4.01% 7.93% 3.20% 4.82%
Profit (Net Income) Margin
1.03% 2.34% 3.02% 3.53% 4.36% 4.17% 2.96% 4.55% 1.13% 2.35%
Tax Burden Percent
70.54% 73.43% 78.53% 87.48% 73.20% 78.33% 81.58% 60.90% 39.56% 52.49%
Interest Burden Percent
72.28% 87.28% 89.90% 91.14% 94.20% 93.46% 90.44% 94.32% 89.14% 92.89%
Effective Tax Rate
24.00% 24.71% 21.36% 14.46% 28.41% 22.08% 18.95% 39.10% 60.44% 47.51%
Return on Invested Capital (ROIC)
32.07% 50.54% 34.12% 45.38% 359.27% 137.76% 522.34% 0.00% 31.50% 53.04%
ROIC Less NNEP Spread (ROIC-NNEP)
39.18% 55.98% 36.80% 42.69% 360.97% 135.40% 531.05% 0.00% 32.40% 52.47%
Return on Net Nonoperating Assets (RNNOA)
-24.65% -34.86% -16.32% -25.70% -333.13% -113.37% -505.51% 0.00% -25.66% -40.28%
Return on Equity (ROE)
7.41% 15.68% 17.81% 19.67% 26.14% 24.39% 16.83% 23.85% 5.84% 12.77%
Cash Return on Invested Capital (CROIC)
14.26% 65.47% 87.39% -128.37% 402.45% 203.95% -55.41% 0.00% 111.31% -10.38%
Operating Return on Assets (OROA)
5.09% 8.60% 9.08% 9.28% 15.25% 13.57% 8.67% 16.21% 6.95% 10.86%
Return on Assets (ROA)
2.60% 5.51% 6.41% 7.40% 10.51% 9.94% 6.40% 9.31% 2.45% 5.29%
Return on Common Equity (ROCE)
7.38% 15.62% 17.76% 19.66% 26.14% 24.39% 16.83% 23.85% 5.84% 12.77%
Return on Equity Simple (ROE_SIMPLE)
7.41% 15.27% 18.30% 18.25% 24.53% 22.49% 16.56% 24.87% 5.75% 12.33%
Net Operating Profit after Tax (NOPAT)
1,947 3,021 2,988 2,693 3,569 2,487 2,512 2,595 689 1,232
NOPAT Margin
1.65% 2.84% 3.22% 3.24% 4.63% 3.83% 4.41% 4.83% 1.27% 2.27%
Net Nonoperating Expense Percent (NNEP)
-7.11% -5.45% -2.67% 2.69% -1.70% 2.36% -8.71% -1.43% -0.90% 0.57%
Return On Investment Capital (ROIC_SIMPLE)
6.91% 10.80% 11.28% - - - - - - -
Cost of Revenue to Revenue
85.48% 83.10% 81.50% 83.31% 79.88% 83.00% 80.62% 80.90% 82.77% 81.54%
SG&A Expenses to Revenue
11.63% 12.40% 13.64% 12.18% 13.03% 11.38% 13.22% 12.21% 13.19% 13.44%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
12.34% 13.13% 14.41% 12.90% 13.66% 12.08% 13.93% 11.18% 14.03% 14.13%
Earnings before Interest and Taxes (EBIT)
2,381 3,876 3,969 3,680 4,883 3,698 2,281 4,262 1,741 2,617
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,349 4,793 4,814 4,393 5,499 4,273 2,815 4,747 2,206 3,064
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.87 3.43 4.16 3.64 3.85 3.90 3.72 3.44 2.69 2.41
Price to Tangible Book Value (P/TBV)
4.53 8.30 10.32 11.73 5.70 5.79 6.03 5.15 3.88 3.52
Price to Revenue (P/Rev)
0.26 0.52 0.69 0.70 0.69 0.72 0.66 0.63 0.53 0.46
Price to Earnings (P/E)
25.31 22.39 22.68 19.94 15.72 17.36 22.43 13.81 46.87 19.52
Dividend Yield
1.40% 0.78% 0.63% 0.62% 0.63% 0.62% 0.73% 0.80% 0.60% 0.68%
Earnings Yield
3.95% 4.47% 4.41% 5.01% 6.36% 5.76% 4.46% 7.24% 2.13% 5.12%
Enterprise Value to Invested Capital (EV/IC)
3.14 8.13 8.52 4.82 51.31 29.93 12.48 0.00 14.77 5.76
Enterprise Value to Revenue (EV/Rev)
0.18 0.42 0.59 0.64 0.52 0.56 0.53 0.42 0.36 0.32
Enterprise Value to EBITDA (EV/EBITDA)
6.21 9.39 11.37 12.18 7.27 8.46 10.65 4.75 8.80 5.75
Enterprise Value to EBIT (EV/EBIT)
8.73 11.61 13.79 14.54 8.19 9.78 13.15 5.29 11.15 6.73
Enterprise Value to NOPAT (EV/NOPAT)
10.68 14.89 18.32 19.87 11.20 14.54 11.94 8.68 28.18 14.31
Enterprise Value to Operating Cash Flow (EV/OCF)
7.01 11.30 11.94 23.65 7.09 6.84 13.80 5.56 10.03 20.30
Enterprise Value to Free Cash Flow (EV/FCFF)
24.00 11.50 7.15 0.00 10.00 9.82 0.00 4.21 7.97 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.71 0.71 0.72 0.78 0.49 0.47 0.60 0.51 0.40 0.42
Long-Term Debt to Equity
0.68 0.63 0.59 0.65 0.44 0.41 0.43 0.48 0.35 0.37
Financial Leverage
-0.63 -0.62 -0.44 -0.60 -0.92 -0.84 -0.95 -1.01 -0.79 -0.77
Leverage Ratio
2.86 2.84 2.78 2.66 2.49 2.45 2.63 2.56 2.38 2.41
Compound Leverage Factor
2.06 2.48 2.50 2.42 2.34 2.29 2.38 2.42 2.12 2.24
Debt to Total Capital
41.61% 41.67% 41.99% 43.69% 32.67% 32.01% 37.39% 33.96% 28.71% 29.81%
Short-Term Debt to Total Capital
2.05% 5.16% 7.90% 6.83% 2.94% 3.95% 10.44% 1.95% 3.42% 4.07%
Long-Term Debt to Total Capital
39.57% 36.51% 34.10% 36.86% 29.72% 28.06% 26.96% 32.01% 25.30% 25.74%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.25% 0.20% 0.22% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
58.14% 58.13% 57.79% 56.23% 67.33% 67.99% 62.61% 66.04% 71.29% 70.19%
Debt to EBITDA
3.50 2.43 2.31 2.84 1.21 1.33 2.16 1.07 1.95 1.43
Net Debt to EBITDA
-2.94 -2.25 -1.86 -1.14 -2.35 -2.53 -2.76 -2.38 -4.25 -2.38
Long-Term Debt to EBITDA
3.33 2.13 1.88 2.40 1.10 1.16 1.55 1.00 1.72 1.24
Debt to NOPAT
6.02 3.86 3.72 4.64 1.87 2.28 2.42 1.95 6.25 3.57
Net Debt to NOPAT
-5.05 -3.57 -2.99 -1.86 -3.63 -4.35 -3.09 -4.35 -13.61 -5.92
Long-Term Debt to NOPAT
5.72 3.38 3.02 3.91 1.70 2.00 1.74 1.84 5.51 3.08
Altman Z-Score
4.50 4.72 4.92 4.38 5.34 5.52 5.18 4.72 4.57 4.59
Noncontrolling Interest Sharing Ratio
0.38% 0.36% 0.26% 0.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.76 1.59 1.52 1.62 1.77 1.82 1.68 1.85 2.07 1.93
Quick Ratio
1.37 1.24 1.20 1.20 1.37 1.47 1.33 1.54 1.63 1.35
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
866 3,914 7,653 -7,618 3,998 3,682 -1,332 5,350 2,434 -241
Operating Cash Flow to CapEx
522.18% 501.39% 409.55% 171.88% 584.96% 717.93% 355.07% 773.09% 367.36% 166.28%
Free Cash Flow to Firm to Interest Expense
1.31 7.94 19.09 -23.37 14.13 15.22 -6.11 22.11 12.88 -1.30
Operating Cash Flow to Interest Expense
4.49 8.08 11.44 6.94 19.93 21.83 9.97 16.74 10.24 4.67
Operating Cash Flow Less CapEx to Interest Expense
3.63 6.46 8.65 2.90 16.52 18.79 7.16 14.57 7.46 1.86
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
2.52 2.36 2.12 2.09 2.41 2.38 2.16 2.05 2.17 2.25
Accounts Receivable Turnover
49.70 57.36 53.25 56.28 70.33 62.66 60.90 50.39 44.55 49.04
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
42.34 34.03 29.51 30.52 35.67 35.17 34.29 34.81 37.65 41.57
Accounts Payable Turnover
17.02 14.97 15.53 16.24 15.87 15.79 12.86 13.31 19.24 20.56
Days Sales Outstanding (DSO)
7.34 6.36 6.85 6.49 5.19 5.82 5.99 7.24 8.19 7.44
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
21.44 24.38 23.50 22.48 23.00 23.11 28.38 27.42 18.97 17.76
Cash Conversion Cycle (CCC)
-14.10 -18.01 -16.65 -15.99 -17.81 -17.29 -22.39 -20.18 -10.78 -10.31
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
6,613 5,532 6,425 11,090 779 1,208 2,403 -1,441 1,314 3,059
Invested Capital Turnover
19.39 17.79 10.60 14.00 77.66 35.94 118.32 -846.72 24.87 23.38
Increase / (Decrease) in Invested Capital
1,081 -893 -4,665 10,311 -429 -1,195 3,844 -2,755 -1,745 1,473
Enterprise Value (EV)
20,788 45,001 54,749 53,499 39,971 36,154 29,991 22,525 19,409 17,624
Market Capitalization
30,550 55,731 63,635 58,489 52,920 46,983 37,749 33,808 28,780 24,911
Book Value per Share
$135.99 $132.09 $120.94 $125.10 $103.73 $90.90 $74.07 $68.89 $71.66 $69.80
Tangible Book Value per Share
$56.01 $54.52 $48.73 $38.81 $70.13 $61.23 $45.66 $45.93 $49.72 $47.77
Total Capital
28,166 27,974 26,496 28,597 20,388 17,703 16,230 14,903 14,989 14,740
Total Debt
11,721 11,656 11,126 12,494 6,660 5,666 6,069 5,061 4,304 4,394
Total Long-Term Debt
11,144 10,213 9,034 10,541 6,060 4,967 4,375 4,770 3,792 3,794
Net Debt
-9,832 -10,786 -8,945 -5,013 -12,949 -10,829 -7,758 -11,283 -9,371 -7,287
Capital Expenditures (CapEx)
568 794 1,120 1,316 964 736 612 524 527 522
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-6,982 -8,763 -7,845 -5,071 -6,380 -5,368 -3,804 -5,312 -2,592 -1,679
Debt-free Net Working Capital (DFNWC)
13,453 12,557 11,097 11,515 10,847 9,658 8,565 8,287 8,880 8,159
Net Working Capital (NWC)
12,876 11,114 9,005 9,562 10,247 8,959 6,871 7,996 8,368 7,559
Net Nonoperating Expense (NNE)
733 537 186 -241 202 -220 829 147 75 -44
Net Nonoperating Obligations (NNO)
-9,832 -10,786 -8,945 -5,013 -12,949 -10,829 -7,758 -11,283 -9,371 -7,287
Total Depreciation and Amortization (D&A)
968 917 845 713 616 575 534 485 465 447
Debt-free, Cash-free Net Working Capital to Revenue
-5.93% -8.24% -8.45% -6.10% -8.27% -8.27% -6.68% -9.88% -4.77% -3.09%
Debt-free Net Working Capital to Revenue
11.42% 11.80% 11.95% 13.86% 14.06% 14.88% 15.05% 15.41% 16.33% 15.03%
Net Working Capital to Revenue
10.93% 10.45% 9.70% 11.51% 13.28% 13.81% 12.07% 14.87% 15.39% 13.92%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$10.01 $20.09 $22.20 $22.79 $25.47 $20.20 $12.24 $16.94 $4.11 $8.54
Adjusted Weighted Average Basic Shares Outstanding
120.64M 120.65M 124.97M 126.63M 128.86M 132.11M 135.57M 137.68M 149.32M 148.30M
Adjusted Diluted Earnings per Share
$9.98 $20.00 $22.08 $22.67 $25.31 $20.10 $12.16 $16.81 $4.07 $8.44
Adjusted Weighted Average Diluted Shares Outstanding
120.64M 120.65M 124.97M 126.63M 128.86M 132.11M 135.57M 137.68M 149.32M 148.30M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
120.64M 120.65M 124.97M 126.63M 128.86M 132.11M 135.57M 137.68M 149.32M 148.30M
Normalized Net Operating Profit after Tax (NOPAT)
1,947 3,021 2,988 2,693 3,569 2,487 2,512 2,595 1,219 1,232
Normalized NOPAT Margin
1.65% 2.84% 3.22% 3.24% 4.63% 3.83% 4.41% 4.83% 2.24% 2.27%
Pre Tax Income Margin
1.46% 3.18% 3.84% 4.04% 5.96% 5.33% 3.62% 7.48% 2.85% 4.48%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
3.61 7.86 9.90 11.29 17.25 15.28 10.46 17.61 9.21 14.07
NOPAT to Interest Expense
2.95 6.13 7.45 8.26 12.61 10.28 11.53 10.72 3.64 6.62
EBIT Less CapEx to Interest Expense
2.75 6.25 7.10 7.25 13.85 12.24 7.66 15.45 6.42 11.26
NOPAT Less CapEx to Interest Expense
2.09 4.52 4.66 4.22 9.21 7.24 8.72 8.56 0.86 3.82
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
35.50% 17.35% 13.99% 12.07% 9.59% 10.75% 15.75% 8.99% 28.83% 13.48%
Augmented Payout Ratio
102.80% 80.68% 88.79% 14.76% 63.65% 50.28% 80.51% 146.45% 45.77% 43.65%

Quarterly Metrics And Ratios for Humana

This table displays calculated financial ratios and metrics derived from Humana's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
8.45% 10.40% 11.26% 10.44% 10.73% 17.93% 15.90% 13.04% 11.56% 6.58% 10.16%
EBITDA Growth
46.01% -121.26% -26.54% -17.35% -27.25% -181.50% -10.29% 12.29% 28.38% 12.89% -15.33%
EBIT Growth
57.80% -56.85% -32.34% -21.42% -32.08% -1,302.70% -13.37% 13.00% 31.83% 19.35% -18.85%
NOPAT Growth
64.56% -56.03% -40.02% -21.41% -30.42% -380.65% -14.00% 46.05% 35.45% 103.28% 84.78%
Net Income Growth
68.07% -26.48% -42.17% -29.08% -40.31% -2,900.00% -30.43% 37.16% 33.12% -38.46% -22.08%
EPS Growth
68.58% -35.14% -40.69% -26.63% -38.10% -5,200.00% -28.54% 39.78% 35.39% 27.27% -20.69%
Operating Cash Flow Growth
-21.75% 92.60% 48.40% -61.81% -93.67% -39.15% -85.19% 231.18% 2,114.24% -5,240.63% 198.17%
Free Cash Flow Firm Growth
88.76% -324.99% -374.27% -175.09% -149.48% -86.33% -75.65% 486.03% 285.65% 146.28% 238.06%
Invested Capital Growth
39.38% 19.54% 299.33% 241.04% 470.58% -13.90% -205.68% -160.94% -115.59% -42.06% -109.49%
Revenue Q/Q Growth
9.92% -0.63% -0.48% -0.24% 11.90% 0.15% -1.21% 0.02% 19.18% -1.58% -3.65%
EBITDA Q/Q Growth
551.09% -143.09% -20.02% -6.08% 783.57% -114.31% -10.01% -17.33% 665.75% -84.25% 12.64%
EBIT Q/Q Growth
365.19% -185.12% -24.49% -7.42% 363.60% -136.72% -12.30% -19.98% 4,567.57% -97.36% 14.39%
NOPAT Q/Q Growth
502.64% -168.53% -35.79% -7.12% 481.79% -126.34% -15.86% -17.77% 1,439.91% -91.93% 42.88%
Net Income Q/Q Growth
281.84% -242.29% -29.20% -8.25% 236.85% -165.06% -13.18% -22.78% 6,977.78% -101.51% 71.16%
EPS Q/Q Growth
279.76% -243.97% -29.18% -8.02% 244.10% -163.19% -12.40% -22.39% 12,437.50% -100.85% 71.35%
Operating Cash Flow Q/Q Growth
162.69% -128.42% 53.17% 186.76% 105.93% -669.81% -60.58% -52.50% 230.43% -160.65% 781.44%
Free Cash Flow Firm Q/Q Growth
51.64% 80.54% 13.34% -37.85% -1,067.66% -76.27% -76.28% -9.17% 167.28% -57.72% 476.07%
Invested Capital Q/Q Growth
19.73% 23.19% -3.70% -1.88% 2.69% 305.42% 31.86% -157.80% -123.86% 829.28% -113.59%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
17.37% 13.12% 14.55% 15.24% 15.15% 13.91% 17.70% 17.71% 18.26% 17.19% 19.36%
EBITDA Margin
6.43% -1.57% 3.62% 4.50% 4.78% -0.78% 5.48% 6.01% 7.27% 1.13% 7.07%
Operating Margin
6.27% -1.86% 2.48% 3.86% 4.17% -1.32% 4.56% 5.37% 6.43% 0.55% 5.14%
EBIT Margin
5.76% -2.39% 2.79% 3.68% 3.96% -1.68% 4.59% 5.17% 6.46% 0.16% 6.14%
Profit (Net Income) Margin
3.87% -2.34% 1.63% 2.30% 2.50% -2.04% 3.14% 3.57% 4.63% -0.08% 5.23%
Tax Burden Percent
73.45% 79.23% 73.73% 73.86% 72.88% 91.37% 75.59% 75.75% 76.70% 25.35% 91.98%
Interest Burden Percent
91.36% 123.50% 79.39% 84.53% 86.45% 132.81% 90.59% 91.32% 93.46% -191.89% 92.71%
Effective Tax Rate
24.01% 0.00% 23.81% 24.29% 24.75% 0.00% 23.32% 23.45% 22.24% 0.00% 8.25%
Return on Invested Capital (ROIC)
84.30% -25.23% 162.24% 403.97% 165.44% -16.38% 0.00% 320.35% 115.22% 4.10% 102.72%
ROIC Less NNEP Spread (ROIC-NNEP)
87.12% -22.29% 162.71% 405.14% 166.77% -13.38% 0.00% 321.31% 116.05% 5.60% 101.75%
Return on Net Nonoperating Assets (RNNOA)
-52.28% 14.03% -150.14% -385.59% -145.69% 8.33% 0.00% -296.19% -85.94% -2.49% -75.51%
Return on Equity (ROE)
32.01% -11.20% 12.10% 18.38% 19.75% -8.05% 18.04% 24.16% 29.28% 1.62% 27.21%
Cash Return on Invested Capital (CROIC)
4.59% 14.26% -113.09% -128.45% -81.10% 65.47% 0.00% 0.00% 0.00% 87.39% 0.00%
Operating Return on Assets (OROA)
13.72% -6.02% 6.06% 7.73% 8.25% -3.97% 8.80% 9.88% 12.22% 0.35% 11.68%
Return on Assets (ROA)
9.21% -5.89% 3.55% 4.83% 5.20% -4.82% 6.03% 6.83% 8.76% -0.17% 9.96%
Return on Common Equity (ROCE)
31.90% -11.16% 12.06% 18.32% 19.68% -8.02% 17.98% 24.10% 29.21% 1.61% 27.16%
Return on Equity Simple (ROE_SIMPLE)
9.67% 0.00% 7.73% 10.24% 12.31% 0.00% 17.74% 20.01% 18.76% 0.00% 17.27%
Net Operating Profit after Tax (NOPAT)
1,530 -380 555 864 930 -244 925 1,099 1,337 87 1,075
NOPAT Margin
4.77% -1.30% 1.89% 2.92% 3.14% -0.92% 3.50% 4.11% 5.00% 0.39% 4.72%
Net Nonoperating Expense Percent (NNEP)
-2.83% -2.94% -0.47% -1.16% -1.33% -3.00% -0.51% -0.96% -0.83% -1.50% 0.97%
Return On Investment Capital (ROIC_SIMPLE)
4.92% -1.35% - - - -0.87% - - - 0.33% -
Cost of Revenue to Revenue
82.63% 86.88% 85.45% 84.76% 84.85% 86.09% 82.30% 82.29% 81.74% 82.81% 80.64%
SG&A Expenses to Revenue
10.53% 14.26% 11.36% 10.66% 10.27% 14.46% 12.38% 11.63% 11.14% 15.83% 13.43%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
11.10% 14.98% 12.07% 11.37% 10.98% 15.22% 13.14% 12.35% 11.84% 16.64% 14.22%
Earnings before Interest and Taxes (EBIT)
1,851 -698 820 1,086 1,173 -445 1,212 1,382 1,727 37 1,399
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,066 -458 1,063 1,329 1,415 -207 1,447 1,608 1,945 254 1,613
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.80 1.87 2.17 2.70 2.64 3.43 3.52 3.29 3.62 4.16 3.72
Price to Tangible Book Value (P/TBV)
3.93 4.53 4.78 6.34 6.48 8.30 8.06 7.59 8.27 10.32 8.46
Price to Revenue (P/Rev)
0.27 0.26 0.33 0.40 0.39 0.52 0.58 0.56 0.63 0.69 0.66
Price to Earnings (P/E)
18.67 25.31 28.06 26.32 21.39 22.39 19.80 16.39 19.27 22.68 21.57
Dividend Yield
1.34% 1.40% 1.12% 0.95% 1.02% 0.78% 0.71% 0.75% 0.68% 0.63% 0.64%
Earnings Yield
5.36% 3.95% 3.56% 3.80% 4.68% 4.47% 5.05% 6.10% 5.19% 4.41% 4.64%
Enterprise Value to Invested Capital (EV/IC)
2.79 3.14 4.83 6.09 5.66 8.13 0.00 0.00 0.00 8.52 0.00
Enterprise Value to Revenue (EV/Rev)
0.18 0.18 0.23 0.30 0.29 0.42 0.39 0.35 0.44 0.59 0.47
Enterprise Value to EBITDA (EV/EBITDA)
5.52 6.21 7.21 8.52 7.54 9.39 7.62 6.38 7.99 11.37 9.07
Enterprise Value to EBIT (EV/EBIT)
7.22 8.73 9.85 11.21 9.67 11.61 9.19 7.61 9.56 13.79 10.95
Enterprise Value to NOPAT (EV/NOPAT)
8.67 10.68 13.03 14.34 12.33 14.89 11.43 9.38 12.55 18.32 14.79
Enterprise Value to Operating Cash Flow (EV/OCF)
7.69 7.01 0.00 0.00 0.00 11.30 6.69 2.62 3.82 11.94 4.51
Enterprise Value to Free Cash Flow (EV/FCFF)
70.83 24.00 0.00 0.00 0.00 11.50 7.53 2.45 2.85 7.15 3.31
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.75 0.71 0.74 0.77 0.82 0.71 0.69 0.70 0.70 0.72 0.65
Long-Term Debt to Equity
0.71 0.68 0.67 0.70 0.77 0.63 0.56 0.58 0.59 0.59 0.48
Financial Leverage
-0.60 -0.63 -0.92 -0.95 -0.87 -0.62 -1.11 -0.92 -0.74 -0.44 -0.74
Leverage Ratio
2.97 2.86 3.06 3.17 3.20 2.84 3.20 3.19 3.16 2.78 2.95
Compound Leverage Factor
2.71 3.53 2.43 2.68 2.76 3.78 2.90 2.91 2.95 -5.33 2.73
Debt to Total Capital
42.75% 41.61% 42.49% 43.53% 44.94% 41.67% 40.82% 41.01% 41.11% 41.99% 39.37%
Short-Term Debt to Total Capital
1.85% 2.05% 3.71% 3.88% 2.80% 5.16% 7.81% 7.06% 6.61% 7.90% 10.40%
Long-Term Debt to Total Capital
40.90% 39.57% 38.78% 39.65% 42.15% 36.51% 33.01% 33.95% 34.50% 34.10% 28.97%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.22% 0.25% 0.19% 0.19% 0.19% 0.20% 0.19% 0.20% 0.20% 0.22% 0.23%
Common Equity to Total Capital
57.03% 58.14% 57.32% 56.28% 54.87% 58.13% 58.99% 58.79% 58.69% 57.79% 60.39%
Debt to EBITDA
3.33 3.50 3.62 3.24 3.10 2.43 2.23 2.17 2.21 2.31 2.21
Net Debt to EBITDA
-2.48 -2.94 -3.40 -2.80 -2.46 -2.25 -3.75 -3.85 -3.46 -1.86 -3.59
Long-Term Debt to EBITDA
3.18 3.33 3.30 2.95 2.91 2.13 1.80 1.79 1.86 1.88 1.63
Debt to NOPAT
5.22 6.02 6.54 5.45 5.07 3.86 3.35 3.19 3.48 3.72 3.61
Net Debt to NOPAT
-3.88 -5.05 -6.16 -4.71 -4.03 -3.57 -5.62 -5.65 -5.44 -2.99 -5.86
Long-Term Debt to NOPAT
4.99 5.72 5.97 4.96 4.75 3.38 2.71 2.64 2.92 3.02 2.66
Altman Z-Score
4.26 4.28 4.22 4.23 4.11 4.42 3.75 3.57 3.71 4.62 3.86
Noncontrolling Interest Sharing Ratio
0.36% 0.38% 0.33% 0.34% 0.34% 0.36% 0.35% 0.24% 0.25% 0.26% 0.19%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.91 1.76 1.76 1.66 1.67 1.59 1.37 1.37 1.39 1.52 1.35
Quick Ratio
1.47 1.37 1.40 1.37 1.35 1.24 1.15 1.16 1.18 1.20 1.13
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-707 -1,461 -7,506 -8,662 -6,284 649 2,737 11,536 12,701 4,752 11,238
Operating Cash Flow to CapEx
348.42% -342.86% 1,429.23% 1,064.04% 238.98% -2,520.85% 535.04% 1,203.03% 2,998.65% -1,864.36% 2,935.07%
Free Cash Flow to Firm to Interest Expense
-4.42 -8.91 -44.42 -51.56 -39.52 4.45 24.01 96.13 112.40 44.00 110.18
Operating Cash Flow to Interest Expense
2.07 -3.22 10.99 7.22 2.66 -48.86 10.98 26.47 59.18 -47.47 82.87
Operating Cash Flow Less CapEx to Interest Expense
1.48 -4.16 10.22 6.54 1.55 -50.80 8.93 24.27 57.20 -50.02 80.05
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
2.38 2.52 2.17 2.10 2.08 2.36 1.92 1.91 1.89 2.12 1.90
Accounts Receivable Turnover
28.69 49.70 57.97 40.60 31.07 57.36 59.63 41.15 30.45 53.25 52.46
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
44.49 42.34 38.11 36.55 35.17 34.03 31.20 30.71 29.78 29.51 29.92
Accounts Payable Turnover
17.18 17.02 14.51 12.93 13.16 14.97 11.72 11.63 11.73 15.53 12.72
Days Sales Outstanding (DSO)
12.72 7.34 6.30 8.99 11.75 6.36 6.12 8.87 11.99 6.85 6.96
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
21.25 21.44 25.15 28.23 27.75 24.38 31.14 31.39 31.13 23.50 28.70
Cash Conversion Cycle (CCC)
-8.52 -14.10 -18.86 -19.24 -16.00 -18.01 -25.02 -22.52 -19.14 -16.65 -21.74
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
7,918 6,613 5,368 5,574 5,681 5,532 -2,693 -3,952 -1,533 6,425 -881
Invested Capital Turnover
17.69 19.39 85.99 138.15 52.67 17.79 -57.28 77.95 23.05 10.60 21.78
Increase / (Decrease) in Invested Capital
2,237 1,081 8,061 9,526 7,214 -893 -1,812 -10,437 -11,364 -4,665 -10,163
Enterprise Value (EV)
22,090 20,788 25,939 33,928 32,132 45,001 40,058 34,594 41,913 54,749 43,409
Market Capitalization
31,923 30,550 38,136 45,025 42,581 55,731 59,700 55,380 60,023 63,635 60,544
Book Value per Share
$147.13 $135.99 $145.89 $138.35 $133.86 $132.09 $136.79 $134.73 $132.64 $120.94 $128.44
Tangible Book Value per Share
$67.31 $56.01 $66.24 $58.95 $54.50 $54.52 $59.80 $58.39 $58.07 $48.73 $56.56
Total Capital
31,125 28,166 30,646 29,623 29,398 27,974 28,732 28,635 28,244 26,496 26,914
Total Debt
13,306 11,721 13,022 12,895 13,212 11,656 11,728 11,744 11,610 11,126 10,597
Total Long-Term Debt
12,729 11,144 11,886 11,746 12,390 10,213 9,483 9,722 9,743 9,034 7,798
Net Debt
-9,901 -9,832 -12,256 -11,154 -10,505 -10,786 -19,697 -20,843 -18,167 -8,945 -17,198
Capital Expenditures (CapEx)
95 154 130 114 177 283 234 264 223 275 288
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5,182 -6,982 -8,814 -8,708 -8,678 -8,763 -17,618 -18,963 -16,210 -7,845 -15,223
Debt-free Net Working Capital (DFNWC)
16,956 13,453 15,335 14,217 13,929 12,557 12,675 12,502 12,457 11,097 11,459
Net Working Capital (NWC)
16,379 12,876 14,199 13,068 13,107 11,114 10,430 10,480 10,590 9,005 8,660
Net Nonoperating Expense (NNE)
288 303 75 186 191 296 95 143 99 105 -118
Net Nonoperating Obligations (NNO)
-9,901 -9,832 -12,256 -11,154 -10,505 -10,786 -19,697 -20,843 -18,167 -8,945 -17,198
Total Depreciation and Amortization (D&A)
215 240 243 243 242 238 235 226 218 217 214
Debt-free, Cash-free Net Working Capital to Revenue
-4.31% -5.93% -7.66% -7.77% -7.94% -8.24% -17.21% -19.21% -16.95% -8.45% -16.64%
Debt-free Net Working Capital to Revenue
14.10% 11.42% 13.33% 12.69% 12.75% 11.80% 12.38% 12.66% 13.02% 11.95% 12.53%
Net Working Capital to Revenue
13.62% 10.93% 12.35% 11.66% 12.00% 10.45% 10.19% 10.62% 11.07% 9.70% 9.47%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$10.31 ($5.74) $3.99 $5.63 $6.13 ($4.26) $6.74 $7.70 $9.91 ($0.07) $9.45
Adjusted Weighted Average Basic Shares Outstanding
120.69M 120.64M 120.41M 120.40M 120.50M 120.65M 123.11M 123.91M 124.94M 124.97M 126.60M
Adjusted Diluted Earnings per Share
$10.30 ($5.73) $3.98 $5.62 $6.11 ($4.24) $6.71 $7.66 $9.87 ($0.08) $9.39
Adjusted Weighted Average Diluted Shares Outstanding
120.69M 120.64M 120.41M 120.40M 120.50M 120.65M 123.11M 123.91M 124.94M 124.97M 126.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
120.69M 120.64M 120.41M 120.40M 120.50M 120.65M 123.11M 123.91M 124.94M 124.97M 126.60M
Normalized Net Operating Profit after Tax (NOPAT)
1,530 -380 555 864 930 -244 925 1,099 1,337 87 1,075
Normalized NOPAT Margin
4.77% -1.30% 1.89% 2.92% 3.14% -0.92% 3.50% 4.11% 5.00% 0.39% 4.72%
Pre Tax Income Margin
5.27% -2.95% 2.21% 3.11% 3.42% -2.23% 4.16% 4.72% 6.04% -0.32% 5.69%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
11.57 -4.26 4.85 6.46 7.38 -3.05 10.63 11.52 15.28 0.34 13.72
NOPAT to Interest Expense
9.57 -2.32 3.28 5.14 5.85 -1.67 8.11 9.16 11.83 0.80 10.54
EBIT Less CapEx to Interest Expense
10.98 -5.20 4.08 5.79 6.26 -4.99 8.58 9.32 13.31 -2.20 10.89
NOPAT Less CapEx to Interest Expense
8.97 -3.26 2.51 4.46 4.74 -3.61 6.06 6.96 9.86 -1.74 7.72
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
25.04% 35.50% 31.98% 25.54% 22.17% 17.35% 14.01% 12.23% 12.89% 13.99% 13.61%
Augmented Payout Ratio
31.39% 102.80% 130.66% 126.07% 132.80% 80.68% 82.73% 62.42% 50.39% 88.79% 51.91%

Frequently Asked Questions About Humana's Financials

When does Humana's fiscal year end?

According to the most recent income statement we have on file, Humana's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Humana's net income changed over the last 9 years?

Humana's net income appears to be on an upward trend, with a most recent value of $1.21 billion in 2024, falling from $1.28 billion in 2015. The previous period was $2.48 billion in 2023. Find out what analysts predict for Humana in the coming months.

What is Humana's operating income?
Humana's total operating income in 2024 was $2.56 billion, based on the following breakdown:
  • Total Gross Profit: $17.10 billion
  • Total Operating Expenses: $14.54 billion
How has Humana revenue changed over the last 9 years?

Over the last 9 years, Humana's total revenue changed from $54.29 billion in 2015 to $117.76 billion in 2024, a change of 116.9%.

How much debt does Humana have?

Humana's total liabilities were at $30.03 billion at the end of 2024, a 2.3% decrease from 2023, and a 109.6% increase since 2015.

How much cash does Humana have?

In the past 9 years, Humana's cash and equivalents has ranged from $2.22 billion in 2024 to $5.06 billion in 2022, and is currently $2.22 billion as of their latest financial filing in 2024.

How has Humana's book value per share changed over the last 9 years?

Over the last 9 years, Humana's book value per share changed from 69.80 in 2015 to 135.99 in 2024, a change of 94.8%.



This page (NYSE:HUM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners